Misplaced Pages

PRC200-SS

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from PRC200) Triple reuptake inhibitor investigated by the Mayo Clinic Pharmaceutical compound
PRC200-SS
Identifiers
IUPAC name
  • (1S,2S)-3-(Methylamino)-2-naphthalen-2-yl-1-phenylpropan-1-ol
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
ECHA InfoCard100.207.294 Edit this at Wikidata
Chemical and physical data
FormulaC20H21NO
Molar mass291.394 g·mol
3D model (JSmol)
SMILES
  • O(c1ccccc1)(CNC)c2cc3ccccc3cc2
InChI
  • InChI=1S/C20H21NO/c1-21-14-19(20(22)16-8-3-2-4-9-16)18-12-11-15-7-5-6-10-17(15)13-18/h2-13,19-22H,14H2,1H3/t19-,20-/m1/s1
  • Key:RSZGIFQDUIROGN-WOJBJXKFSA-N
  (what is this?)  (verify)

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.

Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity, precluding any further drug development.

References

  1. Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, et al. (November 2008). "Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 573–83. doi:10.1124/jpet.108.143610. PMID 18689611. S2CID 12635418.
  2. "Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures.
  3. Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, et al. (April 2011). "Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor". Toxicological Sciences. 120 (2): 269–83. doi:10.1093/toxsci/kfr013. PMID 21258088.
Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
Tricyclic and tetracyclic antidepressants
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Monoamine oxidase inhibitors
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Adjunctive therapies
Miscellaneous
Monoamine reuptake inhibitors
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
Categories: